Background
==========

The parasitic protozoon *Plasmodium falciparum*is responsible for approximately 247 million cases of malaria and one million deaths each year, particularly in sub-Saharan Africa \[[@B1]\]. Anti-mosquito measures and new artemisinin-containing treatments have been recently adopted in hopes of achieving the global eradication of malaria. Novel drugs, vaccines and insecticides, as well as deeper insights into parasite biology, human immunity, and vector behaviour, are essential to support these efforts \[[@B2]\].

Over the past 30 years, experimental observations obtained *in vitro*and in clinical studies have demonstrated the anti-malarial activity of tetracycline and its derivatives \[[@B3]\]. Daily doxycycline (DOX) has been shown to be an effective chemoprophylactic in Thailand \[[@B4]\], Indonesia \[[@B5]\], and Kenya \[[@B6]\]. DOX is currently one of the recommended chemoprophylactic regimens for travellers visiting malaria endemic areas in Southeast Asia, Africa and South America \[[@B7]\]. DOX is now recommended by the French Consensus Conference for chemoprophylaxis in countries with a high prevalence of *P. falciparum*resistance to chloroquine or multiple drugs \[[@B8]\]. However, while no instances of *P. falciparum*malaria clinical failure with DOX have been reported yet, three different phenotypes (low, medium and high DOX susceptibility groups) have been identified among *P. falciparum*clinical isolates \[[@B9]\]. These different phenotypes have been associated with *pfmdt*and *pftetQ*copy number variations and *pftetQ*sequence polymorphisms \[[@B10]\].

DOX has long been known to inhibit protein synthesis in bacteria \[[@B11]\] by binding the S4, S7, S9 and S17 proteins of the small 30S ribosomal subunit and various ribonucleic acids of the 16S rRNA, which prevents the binding of aminoacyl transfer RNA to site A of the ribosome \[[@B12]\]. In *P. falciparum*, tetracyclines have been reported to directly inhibit mitochondrial protein synthesis \[[@B13]\] and also to decrease dihydroorotate dehydrogenase activity, which is involved in *de novo*pyrimidine synthesis \[[@B14]\]. DOX inhibits *P. falciparum*synthesis of nucleotides and deoxynucleotides \[[@B15]\]. Minocycline, another tetracycline derivative, also decreases the transcription of mitochondrial genes and plastid genes, indicating that it may target these two organelles \[[@B16]\]. More recently, two research groups \[[@B17],[@B18]\] reported specific action by cyclines on the apicoplast of *P. falciparum*via cell biology and transcriptome approaches. Collectively, these published data indicate that organelles from *P. falciparum*seem to be primary targets for cyclines; however, the molecular mechanisms involved in this plastid regulation are not yet clearly defined, particularly at the protein level.

Proteome studies have contributed substantially to our understanding of parasite biology and host-parasite interactions \[[@B19]\]. Mass spectrometry (MS) methods have been used to enable large-scale identification of proteins at different stages of the malarial parasite life cycle \[[@B20],[@B21]\]. However, few proteomic analyses have been undertaken to better understand the mechanisms of drug action or resistance in *P. falciparum*. The effects of chloroquine and artemisinin derivatives on *P. falciparum*have been studied using different proteomic techniques, such as a gel-based approach \[[@B22]\], SELDI (Surface Enhanced Laser Desorption Ionization) TOF (Time of Flight) MS analysis \[[@B23]\] and, more recently, isoleucine-based SIL (Stable Isotope Labelling) \[[@B24]\]. Until now, *P. falciparum*proteome response following doxycycline treatment has not been studied.

The present study aimed to highlight the metabolic pathways that are affected in *P. falciparum*following DOX treatment. To accomplish this objective, two complementary proteomics approaches were used: two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) and isobaric tagging reagents for relative and absolute quantification (iTRAQ). The combination of these two technologies allowed us to identify proteins that are deregulated in response to doxycycline and were involved in various cellular functions such as redox homeostasis, stress response, protein synthesis, lipid synthesis and energy metabolism. These results indicated that *P. falciparum*organelles seem perturbed by DOX treatment, suggesting that these are the drug\'s primary targets.

Methods
=======

*Plasmodium falciparum*growth conditions and protein extraction
---------------------------------------------------------------

Parasites (chloroquine-resistant W2 clone) were maintained in continuous culture as described elsewhere \[[@B25]\], at 10% haematocrit of type A^+^human RBCs suspended in supplemented RPMI 1640 (Invitrogen) and 10% heat-inactivated type A^+^human serum at 37°C in a gas mixture of 5% CO~2,~10% O~2~and 85% N~2~. The medium was changed twice daily. Parasitaemia was monitored daily via microscope by examination of blood smears stained with a RAL^®^555 kit (Réactifs RAL). Parasite synchronization was performed by sorbitol treatment (D-sorbitol, ICN Biomedicals) as described elsewhere \[[@B26]\]. At the ring stage, parasites were or were not exposed to DOX (Sigma) at 10 μM (the IC~50~as previously determined \[[@B27]\]) for a period of 24 h. Parasites at the schizont stages during the second cycle after DOX exposure were extracted from the RBCs. Control and treated groups consisted of four biological replicates for the DIGE experiment and three biological replicates for the iTRAQ experiment. IRBCs were washed 3 times in PBS (Invitrogen) and lysed by 0.1% saponin (Sigma) for 5 min. Free parasites were sedimented by centrifugation (9,300 g for 5 min) and washed with PBS 3 times and stored at -80°C. Parasites were resuspended in 10 mM Tris-HCl buffer (pH 8) and disrupted by ultrasonication (Vibracell 72412, Bioblock Scientific) for 5 min on ice at maximum amplitude. After ultracentrifugation (100,000 g for 1 h at 4°C), soluble protein fractions were recovered from the supernatant and the pellet containing membrane protein fractions was then suspended in 4% (w/v) 3-\[(3-cholamidopropyl)dimethylamonio\]-1-propanesulfonate (CHAPS) (Sigma). All of the fractions were precipitated in 100% acetone (Sigma) to remove lipids, and the protein concentration of each sample was estimated using the Lowry-based DC assay (Biorad) according to the manufacturer\'s instructions. All of the samples were suspended in standard cell lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris base, pH 8.5 (Sigma)) to obtain a protein concentration adjusted to 2.5 μg/μL.

2D-DIGE
-------

Protein samples were minimally labelled with CyDye according to the manufacturer\'s recommended protocols (GE Healthcare). Briefly, soluble protein samples from the control parasites (50 μg) and the DOX-treated parasites (50 μg) were labelled with 400 pmol of either Cy3 or Cy5 (in four biological quadruplicates, with a dye swap) and an internal standard (50 μg) was labelled with 400 pmol of Cy2, freshly dissolved in N, N-dimethylformamide (DMF) (Sigma), and incubated on ice for 30 min in the dark. The reaction was quenched with 1 μL of free lysine (10 nM) by incubation for 10 min on ice. Cy3-, Cy5- and Cy2-labeled samples were then pooled, and an equal volume of 2 × sample buffer was added (8 M urea, 2 M thiourea, 4% (w/v) CHAPS, 10 mM dithiothreitol (DTT), and 1% (v/v) immobilized pH gradient (IPG) Buffer 3-10 (GE Healthcare). The membrane protein samples were treated as described above with either IPG Buffer 4-7 or IPG Buffer 6-11 (GE Healthcare). The mixture of labelled proteins was then separated by two-dimensional gel electrophoresis (2-DE) (See additional file [1](#S1){ref-type="supplementary-material"} for more details).

2-D Image analysis
------------------

Gel images were acquired with a Typhoon^®^Trio Image scanner (GE Healthcare) at different excitation wavelengths (Cy3, 580 BP 30/green (532 nm); Cy5, 670 BP 30/red (633 nm); Cy2, 520 BP 40/blue (488 nm)). Images were cropped with ImageQuant^®^software (GE Healthcare) and further analysed using DeCyder v6.5 (GE Healthcare). The software was used to perform gel alignment, spot averaging and normalization and Student\'s *t*-test to determine which protein spots changed in abundance in response to DOX-treatment. The number of detected spots showing a difference with a *p*-value of \< 0.05 was then determined.

In-gel trypsin digestion
------------------------

After imaging, the gels were stained either with Sypro Ruby (Bio-Rad) according to the manufacturer\'s protocol and then scanned using the typhoon scanner or with Coomassie Brilliant Blue (CBB) G-250 as previously described \[[@B28]\]. Spots of interest were manually excised. Protein spots were digested overnight at 37°C with sequencing-grade trypsin (12.5 μg/mL; Promega Madison) in 50 mM NH~4~HCO~3~(Sigma). The resulting peptides were extracted with 25 mM NH~4~HCO~3~for 15 min, dehydrated with acetonitrile (ACN) (Sigma), incubated with 5% formic acid (Sigma) for 15 min under agitation, dehydrated with ACN, and finally completely dried using a SpeedVac. Samples were then stored at -20°C before analysis by MS.

iTRAQ labelling and strong cation exchange
------------------------------------------

After protein precipitation in acetone, the samples were dissolved in 20 μL of dissolution buffer, reduced, alkylated, trypsin-digested and labelled using the iTRAQ reagents four-plex kit according to the manufacturer\'s instructions (Applied Biosystems). The resulting peptide solutions from control and DOX-treated soluble protein samples were labelled with iTRAQ114 and iTRAQ117, respectively, and incubated at room temperature for 1 h. Labelled peptides were then pooled and acidified by mixing with the cation buffer load iTRAQ reagent for a total volume of 1 ml. The peptide mixture was subsequently fractionated by strong cation exchange (SCX) chromatography (See additional file [1](#S1){ref-type="supplementary-material"} for more details). The elution was monitored by absorbance at 214 and 280 nm (Additional file [2](#S2){ref-type="supplementary-material"}), and 40 fractions were collected. These experiments were conducted in three different biological replicates. The same protocol was applied to the membrane proteins samples, but labelling was done with iTRAQ115 (control) and iTRAQ116 (DOX-treatment). Each fraction of iTRAQ-labelled sample was dried using a Speedvac, reconstituted in 12 μL of buffer (1% v/v formic acid in H~2~O) and analysed by nano-liquid chromatography tandem mass spectrometry (nano-LC-MS/MS).

Protein identification by nano-LC MS/MS
---------------------------------------

Protein digests extracted from excised DIGE gel spots were analysed by nano-LC-ESI-MS/MS. Purification and analysis were performed on a C18 capillary column using a CapLC system (Waters) coupled to a hybrid quadrupole orthogonal acceleration time-of-flight tandem mass spectrometer (Q-TOF Ultima, Waters). Chromatographic separations were conducted on an RP capillary column (AtlantisTM dC18, 3 μm, 75 μm × 150 mm Nano EaseTM, Waters) with a 180-200 nl.min^-1^rate of flow (See additional file [1](#S1){ref-type="supplementary-material"} for more details).

DIGE protein database search
----------------------------

The data were searched using Mascot software against the *P. falciparum*National Center for Biotechnology Information non-redundant protein database (NCBInr, NIH, Bethesda, MD, March 27^th^, 2008). Search parameters allowed for one missed tryptic cleavage site, the carbamidomethylation of cysteine, and the possible oxidation of methionine; the precursor and product ion mass error tolerance was \< 0.2 Da. All identified peptides had a Mascot score greater than 28 (*P. falciparum*, 12,220 sequences), corresponding to a statistically significant (*p*\< 0.05) confident identification. Moreover, among the positive matches, only protein identifications based on at least two different non-overlapping peptide sequences of more than six amino acids and with a mass tolerance \< 0.05 Da were accepted (Additional file [3](#S3){ref-type="supplementary-material"}). These additional validation criteria struck a balance that limited the number of false positive matches without missing real proteins of interest.

iTRAQ protein database search and quantification
------------------------------------------------

Mascot distiller software (v2.1.1, Matrix Science) was used to convert MassLynx.raw MS/MS data files into mascot generic files (mgf). (See additional file [1](#S1){ref-type="supplementary-material"} for more details). For protein identification, mgf data files were searched against a mixed file of *Homo sapiens*and *P. falciparum*sequences in the NCBInr (NIH, Bethesda, MD) protein database (229,804 sequences on September 12^th^, 2008 for soluble proteins and 230,260 sequences on October 21^st^, 2008 for membrane proteins) using the MASCOT algorithm (v2.2, Matrix Science). (See additional file [1](#S1){ref-type="supplementary-material"} for more details). For protein quantification, data analysis was performed with Multi-Q 1.6.1.1. as described elsewhere \[[@B29]\]. The MassLynx.raw data files from the Q-TOF Ultima (Waters) were previously converted into files of the mzXML format by the massWolf program \[[@B30]\]. (See additional file [1](#S1){ref-type="supplementary-material"} for more details). Geometric means of the ratios of DOX-treated protein to control protein (iTRAQ117/iTRAQ114 for soluble proteins and iTRAQ116/iTRAQ115 for membrane proteins) and the standard deviation were calculated. Proteins with ratios ≤ 0.80 or ≥ 1.20 between DOX-treated and untreated experimental conditions were considered regulated proteins, as reported elsewhere \[[@B31]\].

Bioinformatics predictions of biological processes and subcellular localization of identified proteins
------------------------------------------------------------------------------------------------------

The NCBI GI (GeneInfo Identifier) numbers of *P. falciparum*proteins identified were converted into standard gene names for retrieval from the UniprotKB ID module \[[@B32]\]. Then, in UniprotKB, PlasmoDB accession numbers of proteins were retrieved for further analysis. Biological processes and subcellular localization of differentially expressed proteins were assessed using Gene Ontology annotations downloaded from PlasmoDB \[[@B33]\]. The transit peptides that enable proteins to target the apicoplast were identified by the PlasmoAP tool \[[@B34]\].

Quantitative real-time RT-PCR
-----------------------------

The same parasite cultures used for the proteomic analysis were also used to perform quantitative RT-PCR. Total RNA was extracted with TRIZOL^®^reagent following the manufacturer\'s recommendations (Invitrogen) and treated with DNase (DNAfree^®^, Ambion). Total RNA was quantified with the NanoDrop ND-1000 (Labtech), followed by quality assessment with the 2100 Bioanalyzer (Agilent Technologies) according to the manufacturer\'s protocol. Acceptable A260/A280 ratios were in the range of 1.8-2.2. Acceptable rRNA ratios (28S/18S) needed to be \> 0.9, and RIN (RNA Integrity Number) values needed to be \> 8.0. Total RNA (1 μg) was reverse transcribed with the High-Capacity cDNA Archive Kit as described by the manufacturer (Applied Biosystems). The primer pairs used (Eurogentec), (Additional file [4](#S4){ref-type="supplementary-material"}) were designed with Primer Express software v2.0 (Applied Biosystems). Real-time transcript quantification was performed using a 7900HT Fast Real-Time PCR system (Applied Biosystems). Amplification reactions and the 2^-ΔΔCt^method of relative quantification to estimate relative expression of mRNA targets were performed as previously described \[[@B35]\]. All data were expressed as means ± standard deviation. A two-tailed Student\'s *t*-test was employed to compare RT-PCR gene expression levels. Statistical significance was defined as *p*\< 0.05.

Results
=======

Phenotypic effect of DOX treatment
----------------------------------

Ring stage parasites (\> 95%) were incubated with 10 μM DOX (*i.e*. corresponding to IC~50~) for 24 h followed by a chase period until the end of the successive cycle at 84 h. Then, parasites were collected at the schizont stage for several reasons. First, DOX exerts delayed effects against *P. falciparum*\[[@B36]\], *i.e*. exposing the parasites to DOX does not lead to phenotypic effects at the end of the first cycle but instead at the end of the successive cycle. A chase period was applied because continuous DOX exposure leads to almost 100% parasite lethality. Secondly, this drug has an increased potency against the schizont stage \[[@B17]\], and finally, protein synthesis in parasites is maximal during trophozoïte and schizont stages \[[@B37]\]. At the beginning of the experiments, all cultures had a parasitaemia equal to 2%. At the end of the experiments, parasitaemia obtained from untreated and DOX-treated iRBCs were 7.9% ± 0.7 and 3.7% ± 0.5, respectively. Both control and treated cultures were at the schizont stage (\> 90%).

*Plasmodium falciparum*response to DOX treatment according to 2D-DIGE analysis
------------------------------------------------------------------------------

Since membrane-associated proteins are generally under-represented by two-dimensional electrophoresis, proteins extracted from the schizont stages were separated into soluble and membrane fractions to circumvent this limitation. Then, four biological replicates from untreated or DOX-treated samples were divided into soluble or membrane protein fractions and their protein expression profiles were compared using 2D-DIGE methods. After imaging, DeCyder software was used to detect spot levels that were significantly deregulated by DOX treatment (Figure [1](#F1){ref-type="fig"} and additional file [5](#S5){ref-type="supplementary-material"}). Among the three type of gels (with 18-cm 3-10, 4-7 and 6-11 linear IPG strips), a total of 150 spots were considered to be significantly deregulated (45, 45 and 60 spots respectively in the membranaire protein gels with 4-7 linear IPG strip, in the membranaire protein gels with 6-11 linear IPG strip and in the soluble protein gels with 3-10 linear IPG strip); 95 spots (63%) were up-regulated and 55 (37%) spots down-regulated in response to DOX treatment (*p*\< 0.05, Student\'s *t*-test, and spot ratios ≤ 0.74 or ≥ 1.35). Thirty five spots (11, 12 and 12 spots respectively) could not be excised manually (invisible after gel coloration compared to scanning images with Typhoon). Then, 115 spots were submitted to identification by nano LC MS/MS (34, 33 and 48 spots respectively). Sixty seven spots were identified by mass spectrometry (MS) (15, 20 and 32 spots respectively). Forty eight spots were not identified (19, 13 and 16 spots respectively) and 20 spots (5, 9 and 6 spots respectively) were not retained, because comigration of proteins confounded the ability to identify individual proteins. Finally, 47 protein spots were identified (Table [1](#T1){ref-type="table"}). However, some proteins were detected in more than one spot, indicating different isoforms. A total of 32 distinct proteins, according to their accession numbers, were finally identified (Figure [1](#F1){ref-type="fig"}) (Table [1](#T1){ref-type="table"}, peptide details in Additional file [2](#S2){ref-type="supplementary-material"}). Among these proteins, 22 were up-regulated, and 10 were down-regulated. They were classified according to their biological functions in Table [1](#T1){ref-type="table"}. Some proteins were identified as being involved in primary metabolism (*e.g*., carbohydrate, protein and amino-acid metabolism, and DNA replication). Proteins involved in anti-oxidative stress (PF08_0131, 1-Cys peroxiredoxin in spot 2251 and PF14_0368, 2-Cys peroxiredoxin in spot 1821) and two proteins with unknown functions were also identified. Several isoforms of the same protein (PF10_0155, enolase in spots 1066 and 1089; PF14_0598, glyceraldehyde-3-phosphate dehydrogenase in spots 1288, 1295 and 1325 in Figure [1A](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}) were identified in adjacent spots.

###### 

Differentially expressed proteins in DOX-treated parasites (DIGE quantification).

  Accession number   Name                                                                       Spot       MASCOT score   Peptides matched   **Ratios**^**a**^   **Biological process**^**b**^            **Predicted Localization**^**c**^   **Fraction**^**d**^
  ------------------ -------------------------------------------------------------------------- ---------- -------------- ------------------ ------------------- ---------------------------------------- ----------------------------------- ---------------------
  PF13_0304          Elongation factor 1 alpha                                                  1078       236            5                  2.85\*              Translation                              Cytoplasm                           S
                                                                                                1111       226            4                  2.65\*                                                                                           S
                                                                                                1143       246            5                  2.42\*                                                                                           S
                                                                                                1026       309            6                  2.31\*                                                                                           S
                                                                                                848        411            9                  2.04\*\*                                                                                         M (2)
                                                                                                833        306            6                  2.03\*\*                                                                                         M (2)
                                                                                                1168       254            6                  1.65\*                                                                                           S
  PF13_0143          Phosphoribosylpyrophosphate synthetase                                     964        174            3                  2.36\*              Carbohydrate metabolism                  Apicoplast                          M (2)
  PFB0445c           DEAD box helicase, UAP56                                                   2246       138            2                  2.25\*              Nucleic acid binding                     Unknown                             S
  PFI1105w           Phosphoglycerate kinase                                                    1025       515            10                 2.14\*              Carbohydrate metabolism                  Unknown                             S
                                                                                                993        343            6                  2.07\*                                                                                           S
  PF14_0598          Glyceraldehyde-3-phosphate dehydrogenase                                   1288       114            2                  2.13\*              Carbohydrate metabolism                  Cytoplasm                           S
                                                                                                1295       276            5                  1.89\*                                                                                           S
                                                                                                1325       472            8                  1.81\*                                                                                           S
  **PFI1090w**       **S-adenosylmethionine synthetase**                                        **1236**   **88**         **2**              **1.99\***          **One carbon compound metabolism**       **Cytoplasm**                       **M (1)**
  PFF1300w           Putative pyruvate kinase                                                   800        217            4                  1.95\*              Carbohydrate metabolism                  Apicoplast                          S
                                                                                                788        120            3                  1.86\*                                                                                           S
                                                                                                1672       110            2                  1.70\*                                                                                           M (1)
                                                                                                553        149            3                  1.61\*\*                                                                                         M (2)
  PF14_0368          2-Cys peroxiredoxin                                                        1821       116            2                  1.94\*              Anti oxidative stress                    Unknown                             M (2)
  PFE0690c           Rab1 protein                                                               2221       171            4                  1.89\*\*            Intracellular protein transport          Cytoplasm                           S
  PF11_0396          Protein phosphatase 2C                                                     2309       144            2                  1.84\*              Protein amino acid dephosphorylation     Cytoplasm                           S
  **PFF1335c**       **4-methyl-5(B-hydroxyethyl)-thiazol Monophosphate biosynthesis enzyme**   **2198**   **282**        **5**              **1.69\***          **Thiamin biosynthesis**                 **Cytoplasm**                       **S**
  MAL13P1.283        TCP-1/cpn60 chaperonin family                                              958        828            13                 1.64\*              Protein folding                          Cytoplasm                           M (1)
                                                                                                936        315            6                  1.38\*                                                                                           M (1)
  **PFF1155w**       **Hexokinase**                                                             **795**    **123**        **3**              **1.61\***          **Carbohydrate metabolism**              **Unknown**                         **S**
  PF14_0425          Fructose-bisphosphate aldolase                                             1180       552            10                 1.60\*\*\*          Carbohydrate metabolism                  Unknown                             S
                                                                                                917        561            10                 1.43\*                                                                                           M (2)
  PF14_0076          Plasmepsin 1 precursor                                                     1406       215            4                  1.58\*\*\*          Haemoglobin Catabolism                   Membrane                            S
  **MAL8P1.69**      **14-3-3 protein**                                                         **1647**   **71**         **2**              **1.54\***          **Protein folding**                      **Unknown**                         **S**
  **PF08_0131**      **1-Cys peroxiredoxin**                                                    **2251**   **83**         **2**              **1.52\***          **Anti oxidative stress**                **Unknown**                         **M (1)**
  **PF08_0074**      **DNA/RNA-binding Protein Alba**                                           **1237**   **113**        **3**              **1.51\***          **Nucleic acid binding**                 **Nucleus**                         **M (2)**
  **PF14_0486**      **Elongation factor 2**                                                    **1264**   **164**        **4**              **1.48\***          **Translation**                          **Cytoplasm**                       **S**
  PF13_0214          Elongation factor 1-gamma                                                  1984       77             2                  1.47\*              Translation                              Apicoplast                          S
  PF10_0155          Enolase                                                                    1066       439            8                  1.43\*\*            Carbohydrate metabolism                  Cytoplasm                           M (1)
                                                                                                1089       584            10                 1.35\*                                                                                           M (1)
  PFL0960w           D-ribulose-5-phosphate 3-epimerase                                         2248       94             2                  1.35\*\*            Carbohydrate metabolism                  Unknown                             M (1)
  PF11_0117          Replication factor C subunit 5                                             1020       106            2                  0.70\*              DNA replication                          Nucleus                             M (2)
  PF08_0109          Proteasome subunit alpha type 5                                            2057       79             2                  0.63\*              Ubiquitin dependent protein catabolism   Unknown                             S
  PFL0185c           Nucleosome assembly protein 1                                              967        170            4                  0.61\*\*            Nucleosome assembly                      Nucleus                             S
  PF11_0313          60S ribosomal protein P0                                                   2081       100            2                  0.60\*              Translation                              Mitochondrion                       M (1)
  PF11_0282          Deoxyuridine 5\'-triphosphate nucleotidohydrolase                          2332       306            5                  0.60\*              DNA replication                          Nucleus                             S
  **MAL8P1.95**      **Conserved *Plasmodium*protein**                                          **1532**   **241**        **3**              **0.58\***          **Unknown**                              **Unknown**                         **S**
  PF14_0678          Exp-2                                                                      1421       153            3                  0.57\*\*            Unknown                                  Membrane                            M (1)
  PF11_0183          GTP-binding nuclear protein ran/tc4                                        1451       98             2                  0.49\*              Nucleus transport                        Nucleus                             M (2)
  PF13_0033          26S proteasome regulatory subunit                                          854        341            8                  0.47\*              Ubiquitin dependent protein catabolism   Nucleus                             M (2)
  PF14_0359          HSP40, Subfamily A                                                         648        204            4                  0.35\*              Protein folding                          Unknown                             M (2)

In bold: differentially expressed proteins commonly identified in DIGE and iTRAQ. ^a^Significant modification in protein ratios between DOX and control cells with \* *P*\< 0.05, \*\* *P*\< 0.01, \*\*\* *P*\< 0.001, Student\'s *t*-test. ^b^Data depicted from PlasmoDB (gene ontology biological process annotation). ^c^Data depicted from PlasmoDB (gene ontology location annotation or PlasmoAP to predict apicoplast addressing). ^d^S = soluble, pI 3-10; M = membrane (1) corresponds to pI 4-7 and (2) to pI 6-11.

![**Examples of 2D and 3D representations of fluorescence intensity of spots that were up and down regulated in response to DOX treatment, as visualized with Decyder software in 2D-DIGE analysis**. (A) In the soluble proteins gel with pI 3-10, spot 2057 was down regulated under DOX treatment and was identified as a putative protein: proteasome subunit alpha type 5 (PF08_0109). (B) In the membrane proteomic map with pI 4-7, spots 936 and 958 were up regulated under DOX treatment and identified as isoforms of the same putative protein: TCP-1/cpn60 chaperon family (MAL13P1.283). (C) In the membrane proteomic map with pI 6-11, spot 553 was up regulated and identified as a putative pyruvate kinase (PFF1300w).](1475-2875-9-141-1){#F1}

*Plasmodium falciparum*response to DOX treatment according to iTRAQ analysis
----------------------------------------------------------------------------

The same soluble and membrane protein extracts used for 2D-DIGE analysis were subjected to iTRAQ analysis. For this analysis, three biological replicates from untreated or DOX-treated parasites were digested, and the peptides were labelled with different isobaric tags. Of the soluble protein samples, 422 proteins were confidently identified including 246 plasmodial proteins (58.3%) and 176 human proteins (41.7%) in the three biological replicates. Among them, 169 were quantified (*i.e*., with at least 4 labelled, non-degenerated peptides), including 14 human proteins (8.3%) and 155 plasmodial proteins (91.7%). Twenty-two proteins displayed significant differences in expression levels (proteins with fold change ≤ 0.80 or ≥ 1.20 were considered as differentially expressed proteins); 18 of these proteins were up-regulated, and four were down-regulated following DOX exposure (Table [2](#T2){ref-type="table"}). In membrane protein samples, 308 proteins were confidently identified, including 204 plasmodial proteins (66.2%) and 104 human proteins (33.8%) in the three biological replicates. Among them, 156 were quantified, including 9 human proteins (5.8%) and 147 plasmodial proteins (94.2%). Eighteen proteins displayed significant differences in expression; 14 of these proteins were up-regulated and four were down-regulated following DOX exposure. In total, 40 proteins were differentially expressed in response to DOX treatment (Table [2](#T2){ref-type="table"}); 80% were up-regulated (32 out of 40), and 20% were down-regulated (8 out of 40). The proteins up-regulated by DOX treatment were associated with haemoglobin catabolism, protein synthesis, protein processing, anti-oxidative stress and phospholipid metabolism. Down-regulated proteins were mostly associated with protein synthesis/processing or nuclear transport. A substantial proportion of the proteins (20%, 8 out of 40) have not been assigned to a biological function yet. Two up-regulated proteins were identified as human proteins: biliverdine reductase and S100-calcium binding protein A4. Their function and location in human cells were precised in Table [2](#T2){ref-type="table"}.

###### 

Differentially expressed proteins in DOX-treated parasites (iTRAQ quantification).

  **Accession number**^**a**^   Name                                         Peptides quantified   Ratios ± SD       **Biological process**^**b**^        **Predicted Localization**^**c**^
  ----------------------------- -------------------------------------------- --------------------- ----------------- ------------------------------------ -----------------------------------
  PF13_0130                     Vacuolar ATP synthase subunit g              3                     2.47 ± 1.07       Vacuolar acidification               Membrane
  PFC0735w                      40S ribosomal protein S15A putative          3                     1.93 ± 0.71       Translation                          Cytoplasm
  **PF08_0074**                 **DNA/RNA-binding Protein Alba, putative**   **6**                 **1.82 ± 0.08**   **Nucleic acid binding**             **Nucleus**
  MAL13P1.214                   Phosphoethanolamine N-methyltransferase      6                     1.79 ± 0.47       Phosphatidylcholine biosynthesis     Unknown
  PF10_0068                     RNA binding protein putative                 3                     1.76 ± 0.16       Nucleic acid binding                 Apicoplast
  PFB0340c                      Serine repeat antigen 5 (SERA-5)             8                     1.76 ± 0.37       Proteolysis                          Unknown
  PFC0920w                      Histone H2A variant putative                 3                     1.59 ± 0.25       Nucleosome assembly                  Apicoplast
  **PFI1090w**                  **S-adenosylmethionine synthetase**          **5**                 **1.57 ± 0.25**   **One carbon compound metabolism**   **Cytoplasm**
  PFB0915w                      Liver stage antigen-3                        4                     1.54 ± 0.04       Unknown                              Membrane
  PFL1545c                      Chaperonin cpn60                             3                     1.52 ± 0.40       Protein folding                      Apicoplast
  PFF0835w                      Conserved *Plasmodium*protein                5                     1.50 ± 0.01       Unknown                              Unknown
  PF08_0110                     Rab18 GTPase                                 3                     1.49 ± 0.13       Intracellular protein transport      Cytoplasm
  PF14_0078                     Plasmepsin III\|HAP protein                  6                     1.48 ± 0.04       Haemoglobin Catabolism               Membrane
  PF14_0324                     Hsp70/Hsp90 organizing protein putative      17                    1.46 ± 0.21       Protein folding                      Unknown
  PF10_0115                     QF122 antigen                                9                     1.45 ± 0.04       Nucleic acid binding                 Apicoplast
  PF14_0655                     RNA helicase-1 putative                      5                     1.44 ± 0.01       Translation                          Cytoplasm
  PF14_0201                     Surface protein putative Pf113               6                     1.44 ± 0.07       Unknown                              Membrane
  **PF14_0486**                 **Elongation factor 2**                      **16**                **1.41 ± 0.30**   **Translation**                      **Cytoplasm**
  PF10_0323                     Early transcribed membrane protein 10.2      4                     1.40 ± 0.08       Unknown                              Membrane
  PFL1170w                      Polyadenylate-binding protein putative       12                    1.35 ± 0.05       Transcription                        Unknown
  gi\|544759                    Biliverdin reductase B                       2                     1.35 ± 0.16       Porphyrin metabolism                 Cytoplasm
  PFE0870w                      Transcriptional regulator putative           4                     1.34 ± 0.10       Transcription                        Nucleus
  gi\|4506765                   S100 calcium-binding protein A4              2                     1.34 ± 0.06       Cell growth                          Cytoplasm
  PF11_0062                     Histone H2B                                  7                     1.34 ± 0.12       Nucleosome assembly                  Apicoplast
  PF14_0391                     60S ribosomal protein L1 putative            2                     1.32 ± 0.13       Translation                          Cytoplasm
  **MAL8P1.69**                 **14-3-3 protein**                           **6**                 **1.30 ± 0.19**   **Protein folding**                  **Unknown**
  MAL13P1.56                    M1-family aminopeptidase                     5                     1.28 ± 0.06       Haemoglobin Catabolism               Apicoplast
  PF14_0439                     Leucine aminopeptidase putative              4                     1.27 ± 0.18       Haemoglobin Catabolism               Apicoplast
  PF08_0096                     RNA helicase putative                        3                     1.24 ± 0.04       Transcription                        Unknown
  **PF08_0131**                 **1-Cys peroxiredoxin**                      **9**                 **1.22 ± 0.15**   **Anti oxidative stress**            **Unknown**
  PFE0585c                      Myo-inositol 1-phosphate synthase putative   10                    1.22 ± 0.03       Phospholipid biosynthetic process    Unknown
  PFL1720w                      Serine hydroxymethyltransferase              3                     1.21 ± 0.01       One carbon compound metabolism       Unknown
  PF14_0167                     Prefoldin subunit 2 putative                 4                     0.80 ± 0.05       Protein folding                      Cytoplasm
  PFI1780w                      *Plasmodium*exported protein (PHISTc)        2                     0.80 ± 0.19       Unknown                              Apicoplast
  **MAL8P1.95**                 **Conserved *Plasmodium*protein**            **5**                 **0.76 ± 0.09**   **Unknown**                          **Unknown**
  PFE0290c                      Conserved *Plasmodium*protein                3                     0.75 ± 0.06       Unknown                              Unknown
  PFA0110w                      DnaJ protein putative                        5                     0.74 ± 0.24       Protein folding                      Membrane
  PF08_0087                     Importin alpha putative                      5                     0.73 ± 0.12       Nucleus transport                    Nucleus
  PFD0090c                      *Plasmodium*exported protein (PHISTa)        4                     0.61 ± 0.14       Unknown                              Apicoplast
  PF11_0351                     Heat shock protein hsp70 homologue           6                     0.54 ± 0.04       Protein folding                      Mitochondrion

In bold: differentially expressed proteins commonly identified in DIGE and iTRAQ. ^a^PlasmoDB accession number, except for two human proteins (NCBI accession number). ^b^Data depicted from PlasmoDB (gene ontology biological process annotation). ^c^Data depicted from PlasmoDB (gene ontology location annotation or PlasmoAP to predict apicoplast addressing).

Comparison of differentially expressed proteins identified by 2D-DIGE and iTRAQ
-------------------------------------------------------------------------------

Of the deregulated proteins identified by DIGE, 19% (six out of 32) were also identified by iTRAQ. The proteins identified by both approaches (DIGE and iTRAQ) were similarly deregulated; for example, S-adenosylmethionine synthetase (DIGE fold change of 1.99 in Table [1](#T1){ref-type="table"} and [1](#T1){ref-type="table"}.57 with iTRAQ in Table [2](#T2){ref-type="table"}) and 1-Cys peroxiredoxin (fold change of 1.52 with DIGE and 1.22 with iTRAQ). The metabolic processes in which the proteins are involved are similar and, for the most part, changes in protein expression levels were similar between the two approaches (Figure [2](#F2){ref-type="fig"}). The main metabolic systems identified by both proteomics approaches were protein metabolism, the anti-oxidant response mechanism, nucleic acid binding and transport mechanisms. Both approaches revealed a down-regulation of proteins involved in protein synthesis metabolism and transport mechanism and an up-regulation of proteins involved in protein metabolism and anti-oxidant response mechanisms (Figure [2](#F2){ref-type="fig"}). However, proteins involved in nucleic acid binding were characterized differently by the two methods; these proteins were up-regulated according to the iTRAQ data and down-regulated according to the DIGE data. Proteins involved in carbohydrate metabolism were all up-regulated and only identified by the DIGE method (Table [1](#T1){ref-type="table"}). In addition, proteins involved in specific metabolic pathways were only identified by iTRAQ (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Those proteins identified by iTRAQ alone were either membrane proteins involved in vacuolar acidification or enzymes involved in phospholipid metabolism (Table [2](#T2){ref-type="table"}). Fifteen soluble proteins were identified in the soluble fractions but not in the membrane fractions (Table [1](#T1){ref-type="table"}). Fourteen proteins were identified only in membrane fractions, but only two are actually thought to belong to the membrane, calling into question the effectiveness of the 2D-PAGE approach for characterising membrane proteins. The iTRAQ method, in contrast, allowed identification and quantification of a large number of high molecular weight proteins and membrane proteins (Table [2](#T2){ref-type="table"}).

![**Functional classification of differentially expressed proteins under DOX treatment identified in iTRAQ and DIGE experiments**.](1475-2875-9-141-2){#F2}

Subcellular localization of regulated proteins
----------------------------------------------

As predicted by gene ontology in PlasmoDB and PlasmoAP (for apicoplast addressing), the cellular localization (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}) of the 64 differentially regulated plasmodial proteins identified by the two proteomic approaches was as follows: 21% in the cytoplasm, 19% in the apicoplast, 13% in the membrane, 13% in the nucleus, 5% in the mitochondria and 29% unknown. Cytoplasmic, apicoplastic and membrane proteins were generally up-regulated, while nuclear and mitochondrial proteins were more often down-regulated (Figure [3](#F3){ref-type="fig"}). All of the identified apicoplastic proteins were encoded by the nuclear genome of *P. falciparum*and not by its plastid genome.

![**Number of differentially expressed proteins, identified by iTRAQ and DIGE experiments, corresponding to different functions and subcellular localizations**.](1475-2875-9-141-3){#F3}

RT-PCR quantifications
----------------------

To validate the proteomics results, quantitative RT-PCR was performed because antibodies against *P*. *falciparum*are not commercially available, and the proteomics data suggest that apicoplast function was particularly perturbed by DOX-treatment. Thus, three apicoplast transcripts were chosen to evaluate the modifications observed in this organelle following DOX-treatment. PFI1090w (the S-adenosylmethionine synthetase) and MAL8P1.95 (a conserved *Plasmodium*protein), which had similar expression profiles (up and down regulation respectively) according to both DIGE and iTRAQ, also had similar expression profiles at the transcript level (Table [3](#T3){ref-type="table"}). PF14_0439 (leucine aminopeptidase) was shown to be upregulated by iTRAQ analysis and was also up-regulated at the transcript level. Moreover, mRNA for the *PftufA*, *PfsufB*and *PfclpC*proteins encoded by the plastid genome, which were not quantified at the protein level by DIGE or iTRAQ, were down-regulated at the transcript level. Two transcripts of PF07_0033 (CG4) and PFE1195w (Karyopherin beta) proteins were used as positive controls in RT-PCR experiments (Their qRT-PCR ratios were 1.05 ± 0.09 and 0.98 ± 0.12 respectively) because they were not deregulated in iTRAQ proteomic approach (iTRAQ ratios were 1.01 ± 0.03 and 1.07 ± 0.05 respectively), (Table [3](#T3){ref-type="table"}).

###### 

Quantitative RT-PCR results.

  Accession nr     Description                       DIGE ratios   iTRAQ ratios   **qRT-PCR ratios**^**a**^
  ---------------- --------------------------------- ------------- -------------- ---------------------------
  PFCOMPIRB-TufA   TufA                              NA            NA             0.30 ± 0.04
  PFCOMPIRB-SufB   SufB                              NA            NA             0.32 ± 0.12
  PFCOMPIRB-ClpC   ClpC                              NA            NA             0.26 ± 0.08
  PFI1090w         S-adenosylmethionine synthetase   1.99          1.57 ± 0.25    1.72 ± 0.16
  MAL8P1.95        Conserved *Plasmodium*protein     0.57          0.76 ± 0.09    0.44 ± 0.03
  PF14_0439        Leucine aminopeptidase putative   NA            1.27 ± 0.18    1.48 ± 0.23
  PF07_0033        Cg4 protein                       NA            1.01 ± 0.03    1.05 ± 0.09
  PFE1195w         Karyopherin beta                  NA            1.07 ± 0.05    0.98 ± 0.12

^a^qRT-PCR ratios correspond to the relative expression of target mRNA between the DOX treated and the control (mean of three biological replicates). NA: not available.

Discussion
==========

In the present study, proteome changes was researched in *Plasmodium falciparum*following DOX treatment in order to clarify the action mechanisms of this drug using two proteomic approaches, 2D-DIGE and iTRAQ. These techniques have been shown to be complementary in studying protein changes as they have distinct physicochemical properties that favour identification of different proteins \[[@B38],[@B39]\]; that is the reason why a 19% overlap was observed between deregulated proteins identified by the both methods. Analysis of the DIGE results detected differentially expressed proteins with PTMs (post translational modifications) after DOX treatment (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). In particular, enolase and aldolase have previously been reported to possess several differentially expressed isoforms during the schizont stages of *P. falciparum*\[[@B40]\]; these two proteins are localized in Maurer\'s cleft \[[@B41]\] and in the food vacuole \[[@B42]\]. However, little is known about the role of these PTMs in the plasmodial regulation of protein expression under either physiological conditions or anti-malarial treatment.

Few proteomic studies have been undertaken to elucidate the mechanisms of drug action in *P. falciparum*but all share some common features with the present work \[[@B22],[@B24],[@B43]\]. After exposure to anti-malarial treatment, proteome analysis has generally revealed a low number of differentially expressed proteins with an upregulation of proteins involved in glycolysis, chaperoning or redox metabolism. In a stable isotope labelling experiment after artemisinin and chloroquine treatment in schizont stages of *P. falciparum*, among more than 800 quantified proteins, only 41 and 38 were up-regulated, respectively \[[@B24]\]. However, none of these proteins were associated with heat shock response or glycolysis functions, probably because the design of the study did not allow it, *e.g*. the SILAC method, which explores only newly synthesized proteins, was used. In a gel-based study, arthemeter and lumefantrine treatment were respectively associated with an up-regulation of 22 and 41 proteins \[[@B43]\]. In another study, chloroquine treatment increased the number of oxidized proteins in the schizont stage of parasites \[[@B22]\]. In these two last studies, four glycolysis enzymes (enolase, aldolase, phosphoglycerate kinase and glyceraldehyde-3-phosphate dehydrogenase) and one heat shock protein (HSP 70 homolog) were commonly identified as up-regulated proteins under lumefantrine or chloroquine treatment, which was similar to the results seen under DOX treatment. The increased expression of redox metabolism proteins (1-Cys peroxiredoxin, 2-Cys peroxiredoxin) and 11 other \"associated proteins\" (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}), which have been recently shown to be potential targets of thioredoxin, glutaredoxin and plasmoredoxin \[[@B44]\], might represent another non-specific common feature of parasite responses to drug treatment.

Alternately, some metabolic pathways (Figure [4](#F4){ref-type="fig"}) might represent a specific response of parasites to DOX. Several studies have shown that tetracyclines, which are members of the DOX family, directly inhibit mitochondrial protein synthesis \[[@B13],[@B45],[@B46]\]. This inhibition would lead to a decrease in the mitochondrial respiratory chain activity \[[@B16]\] because the plasmodial mitochondrial genome encodes cytochrome *c*oxidase subunits I and III and apocytochrome *b*. The mitochondrial respiratory chain is coupled to dihydroorotate dehydrogenase activity, which has been shown to be depressed under tetracycline treatment \[[@B14]\]. This enzyme is involved in *de novo*pyrimidine biosynthesis, and its inhibition is associated with decreased levels of nucleotides and deoxynucleotides in *P. falciparum*in response to tetracycline treatment \[[@B15]\]. DOX inhibition of mitochondrial protein synthesis could be responsible for DNA replication impairment as suggested in the present study, *i.e*. replication factor C subunit 5 and deoxyuridine 5\'-3P nucleotidohydrolase were down-regulated (Figure [4](#F4){ref-type="fig"}).

![**Overview of metabolic pathways affected by doxycycline treatment in *P. falciparum*schizont stages adapted from Ginsburg, Hagai**. \'\'Malaria Parasite Metabolic Pathways\'\' <http://sites.huji.ac.il/malaria/>. Metabolic pathways are indicated by boxes and metabolic steps by arrows. Up- and down-regulated proteins under DOX treatment are indicated in red and blue, respectively. Abbreviations: ALA, aminolevulinic acid; DOXP, deoxyxylulose phosphate; ER, endoplasmic reticulum; GA, Golgi apparatus; GA3P, glyceraldehydes-3-phosphate; GPI, glycosyl phosphatidylinositol; Hb, haemoglobin; PEP, phosphoenolpyruvate; PDH, phosphate dehydrogenase; PG, phosphoglycerate; PPT, phosphoenolpyruvate transporter; PYK, pyruvate kinase; TPT, triose phosphate transporter.](1475-2875-9-141-4){#F4}

Two recent works have confirmed specific action by the cyclines on the *P. falciparum*apicoplast \[[@B17],[@B18]\]; replication and transcription of the plastid genome as well as the import of nuclear encoded proteins into the plastid matrices\' were inhibited in response to cycline treatment. Cyclines are assumed to inhibit plastid protein synthesis, but the precise mechanism of action has not yet been identified. The apicoplast genome encodes different tRNAs, rRNA, TufA (a translational elongation factor), SufB (involved in iron metabolism and modification of tRNAs \[[@B47]\]), ClpC (a protease required for nuclear-encoded protein import into the apicoplast) and a DNA dependent RNA polymerase (involved in transcription). This organelle is implicated in fatty acid and isoprenoid precursor synthesis and in heme biosynthesis in tight association with mitochondria \[[@B48]\]. In the present study, ClpC, TufA and SufB were found to be down-regulated under DOX treatment, but only at the transcriptional level. The inhibition of ClpC could explain the defect in protein import into the apicoplast and consequently the overexpression of 12 encoded nuclear proteins that are localized to the apicoplast (Figure [4](#F4){ref-type="fig"}).

Conclusions
===========

The present study has given the first insights into changes in protein regulation in *P. falciparum*upon DOX treatment, suggesting that *P. falciparum*apicoplasts and mitochondria are the targets of DOX. It has also confirmed that 2D-DIGE and iTRAQ are powerful and complementary techniques in studying protein changes in response to drug treatment. However, more experiments will be needed to characterize the specific molecular mechanisms of DOX treatment. In order to prove that DOX inhibits plastid or mitochondrial translational further biochemical approaches would probably be required.
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